Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

160
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
160
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

13.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
13.3K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

146
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
146

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dendrimeric liquid crystals actively modulate cavitation, skin transport pathways, and drug fate during low-frequency sonophoresis.

International journal of pharmaceutics·2026
Same author

Electrospun PVA-PCL/HA nanofiber scaffolds containing mupirocin for surgical wound healing in Sprague Dawley rats.

Journal of pharmaceutical sciences·2026
Same author

Effects of Resveratrol-Loaded Nanoparticles on Follicular Survival, Stromal Integrity and Activity of Endogenous Free-Radical Scavengers in Bovine Ovarian Cortical Slices Cultured In Vitro.

Reproduction in domestic animals = Zuchthygiene·2026
Same author

Development and in vitro evaluation of liposomes and immunoliposomes containing 5-fluorouracil and R-phycoerythrin as a potential phototheranostic system for colorectal cancer.

Beilstein journal of nanotechnology·2026
Same author

Quinazolinones as Bioisosteres of Naphthoquinones: A Path to Potent <i>Hs</i>DHODH Inhibitors with Optimized Properties.

ACS medicinal chemistry letters·2026
Same author

Medical and biological applications of Langevin-type ultrasonic transducers: A narrative review.

Ultrasonics·2025

Related Experiment Video

Updated: Apr 21, 2026

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.4K

Targeted lipid nanoparticles for antisense oligonucleotide delivery.

Raquel Petrilli, Josimar O Eloy, Juliana M Marchetti

  • 1College of Pharmacy, The Ohio State University, 500 W 12th Columbus OH, USA. lee.1339@osu.edu.

Current Pharmaceutical Biotechnology
|October 23, 2014
PubMed
Summary

Antisense oligonucleotides (AS-ODNs), a promising therapy, face delivery challenges. Targeted lipid nanoparticles show potential for enhanced cellular uptake and therapeutic efficacy, but require further clinical evaluation.

More Related Videos

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

24.6K
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.1K

Related Experiment Videos

Last Updated: Apr 21, 2026

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.4K
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

24.6K
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.1K

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Pharmacology

Background:

  • Antisense oligonucleotides (AS-ODNs) are short DNA molecules targeting mRNA to modulate gene expression for therapeutic purposes.
  • Clinical application of AS-ODNs is hindered by poor in vivo stability and low intracellular delivery efficiency.
  • Lipid nanoparticles (LNPs) are being investigated as effective carriers for AS-ODN delivery.

Purpose of the Study:

  • To review strategies for enhancing AS-ODN delivery using targeted lipid nanoparticles.
  • To highlight the potential of active targeting via cell surface receptor ligands to improve AS-ODN efficacy.
  • To assess the current status and future directions for targeted LNP-mediated AS-ODN therapeutics.

Main Methods:

  • Review of literature on AS-ODN delivery systems, focusing on lipid nanoparticles.
  • Analysis of active targeting strategies employing ligands such as cell penetrating peptides (CPPs), transferrin, folate, and antibodies.
  • Evaluation of studies demonstrating enhanced intracellular uptake and therapeutic effects of targeted AS-ODN-loaded LNPs.

Main Results:

  • Targeted lipid nanoparticles demonstrate improved intracellular delivery and enhanced therapeutic effects of AS-ODNs in preclinical studies.
  • Ligands facilitate targeted delivery by binding to overexpressed cell surface receptors, promoting cellular uptake.
  • Strategies include linking various ligands (CPPs, transferrin, folate, antibodies) to LNPs for active targeting.

Conclusions:

  • Targeted lipid nanoparticles represent a promising approach to overcome AS-ODN delivery barriers.
  • Enhanced cellular uptake and reduced toxicity are key benefits of active targeting strategies.
  • Further clinical evaluation is necessary to translate the potential of targeted AS-ODN-loaded LNPs into approved therapies.